|
FR104E
(https=)
|
|
|
|
|
|
US5843708A
(en)
|
1988-01-05 |
1998-12-01 |
Ciba-Geigy Corporation |
Chimeric antibodies
|
|
EP0368684B2
(en)
|
1988-11-11 |
2004-09-29 |
Medical Research Council |
Cloning immunoglobulin variable domain sequences.
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
US5397703A
(en)
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
DE19939653A1
(de)
|
1999-08-13 |
2001-02-22 |
Thomas Huenig |
Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
|
|
JP4210454B2
(ja)
|
2001-03-27 |
2009-01-21 |
日本たばこ産業株式会社 |
炎症性腸疾患治療剤
|
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
|
ATE363290T1
(de)
|
1999-10-04 |
2007-06-15 |
Novartis Vaccines & Diagnostic |
Cd40 antagonist zur behandlung von psoriasis
|
|
EP1261376A1
(en)
|
2000-01-27 |
2002-12-04 |
Genetics Institute, LLC |
Antibodies against ctla4(cd152), conjugates comprising same, and uses thereof
|
|
WO2002011763A1
(en)
|
2000-04-19 |
2002-02-14 |
Tanox, Inc. |
Cd40 antagonists for use in treating psoriasis and other inflammatory skin conditions
|
|
US20030059427A1
(en)
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
|
|
JP4202127B2
(ja)
|
2000-10-02 |
2008-12-24 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
|
|
DE10050935A1
(de)
|
2000-10-11 |
2002-05-02 |
Tegenero Gmbh |
Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
|
|
US8501471B2
(en)
|
2000-10-18 |
2013-08-06 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
|
EP1399187A4
(en)
|
2000-10-18 |
2005-09-21 |
Sloan Kettering Inst Cancer |
APPLICATIONS OF MONOCLONAL ANTIBODY 8H9
|
|
US8414892B2
(en)
|
2000-10-18 |
2013-04-09 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
|
US20020102264A1
(en)
|
2000-10-18 |
2002-08-01 |
Cheung Nai-Kong V. |
Uses of monoclonal antibody 8H9
|
|
NZ526569A
(en)
|
2000-12-14 |
2005-07-29 |
Fujisawa Pharmaceutical Co |
Silenced anti-CD28 antibodies and use thereof for inducing T-cell tolerance, providing immunosupression and treating organ or tissue transplant rejection
|
|
ES2353273T3
(es)
|
2000-12-26 |
2011-02-28 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Anticuerpos anti-cd28.
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
PT1391464E
(pt)
|
2001-04-27 |
2007-11-15 |
Kirin Pharma Kk |
Anticorpo monoclonal anti-cd40
|
|
WO2003029296A1
(en)
|
2001-10-02 |
2003-04-10 |
Chiron Corporation |
Human anti-cd40 antibodies
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
AU2002346581A1
(en)
|
2001-11-26 |
2003-06-10 |
Chiron Corporation |
Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
|
|
US20080199471A1
(en)
|
2002-03-01 |
2008-08-21 |
Bernett Matthew J |
Optimized cd40 antibodies and methods of using the same
|
|
CA2478082C
(en)
|
2002-03-08 |
2016-02-02 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8h9
|
|
DE10212108A1
(de)
|
2002-03-13 |
2003-10-02 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
|
|
CA2489004C
(en)
|
2002-06-13 |
2013-01-08 |
Crucell Holland B.V. |
Agonistic binding molecules to the human ox40 receptor
|
|
DE10230223A1
(de)
|
2002-07-04 |
2004-01-22 |
Tegenero Ag |
Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
|
|
US7052694B2
(en)
|
2002-07-16 |
2006-05-30 |
Mayo Foundation For Medical Education And Research |
Dendritic cell potentiation
|
|
US6693136B1
(en)
|
2002-07-26 |
2004-02-17 |
Abbott Laboratories |
Fluorenes and anthracenes that inhibit P2X3 and P2X2/3 containing receptors
|
|
PL375144A1
(en)
|
2002-07-30 |
2005-11-28 |
Bristol-Myers Squibb Company |
Humanized antibodies against human 4-1bb
|
|
US7291331B1
(en)
|
2002-09-11 |
2007-11-06 |
La Jolla Institute For Allergy And Immunology |
Methods of treating OX40 medicated recall immune responses
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US20070104688A1
(en)
|
2003-02-13 |
2007-05-10 |
City Of Hope |
Small interfering RNA mediated transcriptional gene silencing in mammalian cells
|
|
JP4638876B2
(ja)
|
2003-05-23 |
2011-02-23 |
ワイス |
Ｇｉｔｒリガンド及びｇｉｔｒリガンド関連分子及び抗体及びその使用
|
|
US20090191213A9
(en)
|
2003-07-02 |
2009-07-30 |
Novo Nordisk A/S |
Compositions and methods for regulating NK cell activity
|
|
EP1600164A3
(de)
|
2003-09-22 |
2006-05-17 |
TeGenero AG |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
ATE474598T1
(de)
|
2003-11-04 |
2010-08-15 |
Novartis Vaccines & Diagnostic |
Verwendung von antagonisten-anti-cd40-antikörpern zur behandlung von chronisch lymphozytischer leukämie
|
|
EP1844815B1
(en)
|
2003-11-04 |
2011-09-14 |
Novartis Vaccines and Diagnostics, Inc. |
Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
|
|
EP1680141B8
(en)
|
2003-11-04 |
2011-01-12 |
Novartis Vaccines and Diagnostics, Inc. |
Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
|
|
PT1694360E
(pt)
|
2003-11-04 |
2010-12-13 |
Novartis Vaccines & Diagnostic |
Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento de doenças auto-imunes e inflamatórias e da rejeição ao transplante de orgãos
|
|
CA2544951A1
(en)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
|
|
DE10352900A1
(de)
|
2003-11-11 |
2005-06-16 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
|
|
US20050136055A1
(en)
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
BRPI0417266B8
(pt)
|
2003-12-25 |
2021-05-25 |
Kyowa Hakko Kirin Co Ltd |
anticorpo monoclonal, seu uso e composição farmacêutica
|
|
US20060099203A1
(en)
|
2004-11-05 |
2006-05-11 |
Pease Larry R |
B7-DC binding antibody
|
|
EP2287195B1
(en)
|
2004-07-01 |
2019-05-15 |
Novo Nordisk A/S |
Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
|
|
US20080057070A1
(en)
|
2004-11-04 |
2008-03-06 |
Chiron Corporation |
Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
|
|
DE102004063494A1
(de)
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
Antikörper
|
|
CN101103043A
(zh)
|
2005-01-06 |
2008-01-09 |
诺和诺德公司 |
Kir结合剂和使用其的方法
|
|
US8551483B2
(en)
|
2005-01-06 |
2013-10-08 |
Innate Pharma S.A.S. |
Methods of treating viral infections by administering KIR2DL-binding antibodies
|
|
EP3072522B1
(en)
|
2005-01-06 |
2019-04-24 |
Novo Nordisk A/S |
Anti-kir combination treatments and methods
|
|
US20070161644A1
(en)
|
2005-01-25 |
2007-07-12 |
Stockwell Brent R |
Erastin analogs and uses thereof
|
|
NZ560320A
(en)
|
2005-01-25 |
2011-02-25 |
Prolexys Pharmaceuticals Inc |
Quinoxaline derivatives as antitumor agents
|
|
US8759490B2
(en)
|
2005-03-24 |
2014-06-24 |
Millennium Pharamaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
EP3058955B1
(en)
|
2005-03-24 |
2019-05-29 |
Millennium Pharmaceuticals, Inc. |
Antibodies that bind ov064 and methods of use therefor
|
|
AU2006230099B2
(en)
|
2005-03-25 |
2012-04-19 |
Gitr, Inc. |
GITR binding molecules and uses therefor
|
|
US20060240006A1
(en)
|
2005-04-20 |
2006-10-26 |
Chishih Chu |
Novel antibody structures derived from human germline sequences
|
|
MX2007013584A
(es)
|
2005-04-27 |
2008-04-22 |
Univ Indiana Res & Tech Corp |
Anticuerpos de isoforma de cspcna y sus usos.
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
US7585960B2
(en)
|
2005-05-11 |
2009-09-08 |
Theramab Gmbh |
Nucleic acids encoding superagonistic anti-CD28 antibodies
|
|
WO2006125117A2
(en)
|
2005-05-18 |
2006-11-23 |
Novartis Ag |
Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
|
|
WO2006125143A2
(en)
|
2005-05-18 |
2006-11-23 |
Novartis Ag |
Methods for diagnosis and treatment of proliferative disorders mediated by cd40 signaling
|
|
KR100694508B1
(ko)
|
2005-05-24 |
2007-03-13 |
울산대학교 산학협력단 |
Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
|
|
CA2609269C
(en)
|
2005-05-26 |
2014-08-05 |
Seattle Genetics, Inc. |
Humanized anti-cd40 antibodies and their methods of use
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
US8926979B2
(en)
|
2005-11-01 |
2015-01-06 |
Novartis Ag |
Treatment of cancer or pre-malignant conditions using anti-CD40 antibodies
|
|
JP2009513712A
(ja)
|
2005-11-01 |
2009-04-02 |
ノバルティス アーゲー |
抗ｃｄ４０抗体の使用
|
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
|
|
AU2006321553B2
(en)
|
2005-12-08 |
2012-03-08 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to O8E
|
|
EP1968636A4
(en)
|
2005-12-09 |
2010-06-02 |
Seattle Genetics Inc |
METHOD OF USE OF CD40 BONDING AGENTS
|
|
WO2007076085A2
(en)
|
2005-12-22 |
2007-07-05 |
Prolexys Pharmaceuticals, Inc . |
Fused pyrimidones and thiopyrimidones, and uses thereof
|
|
BRPI0620264A2
(pt)
|
2005-12-22 |
2011-11-08 |
Prolexys Pharmaceuticals Inc |
quinazolonas aril-substituìdas e sua utilização
|
|
US20110008368A1
(en)
|
2006-01-13 |
2011-01-13 |
Board Of Regents, The University Of Texas System |
Methods of modulating the ox40 receptor to treat cancer
|
|
MX2008013508A
(es)
|
2006-04-21 |
2008-10-31 |
Novartis Ag |
Composiciones farmaceuticas de anticuerpos antagonistas anti-cd40.
|
|
EP1854810A1
(en)
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
|
|
WO2007149476A2
(en)
|
2006-06-19 |
2007-12-27 |
Trustees Of Columbia University In The City Of New York |
Assays for non-apoptotic cell death and uses thereof
|
|
KR100745488B1
(ko)
|
2006-07-04 |
2007-08-02 |
학교법인 울산공업학원 |
항-4-1ｂｂ 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물
|
|
WO2008013987A2
(en)
|
2006-07-27 |
2008-01-31 |
Prolexys Pharmaceuticals, Inc. |
N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
|
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
|
KR20090088891A
(ko)
|
2006-11-15 |
2009-08-20 |
메다렉스, 인코포레이티드 |
비티엘에이에 대한 인간 단일클론 항체 및 이용 방법
|
|
US20100189723A1
(en)
|
2007-01-11 |
2010-07-29 |
Peter Andreas Nicolai Reumert Wagtmann |
Anti-kir antibodies, formulations, and uses thereof
|
|
EP2125893A2
(en)
|
2007-01-23 |
2009-12-02 |
Xencor, Inc. |
Optimized cd40 antibodies and methods of using the same
|
|
WO2008103470A2
(en)
|
2007-02-21 |
2008-08-28 |
Trustees Of Columbia University In The City Of New York |
Oncogenic-ras-signal dependent lethal compounds
|
|
JP2010523478A
(ja)
|
2007-03-22 |
2010-07-15 |
スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ |
モノクローナル抗体８ｈ９の使用
|
|
EP2068925A4
(en)
|
2007-05-07 |
2011-08-31 |
Medimmune Llc |
ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
|
|
PT2152258T
(pt)
|
2007-05-10 |
2016-08-18 |
Avalon Pharmaceuticals |
Derivados de fluoreno, antraceno, xanteno, dibenzosuberona e acridina e suas utilizações
|
|
KR20080107050A
(ko)
|
2007-06-05 |
2008-12-10 |
울산대학교 산학협력단 |
항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
|
|
HRP20131167T1
(hr)
|
2007-06-18 |
2014-01-03 |
Merck Sharp & Dohme B.V. |
Antitijela za humani receptor programirane smrti pd-1
|
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
MX2010005099A
(es)
|
2007-11-09 |
2010-05-27 |
Novartis Ag |
Usos de anticuerpos anti-cd40.
|
|
EA201000910A1
(ru)
|
2007-11-30 |
2011-04-29 |
Бристоль-Мейерз Сквибб Компани |
Конъюгат "моноклональное антитело против в7н4/лекарственное средство" и способы его применения
|
|
WO2009082607A2
(en)
|
2007-12-04 |
2009-07-02 |
Alnylam Pharmaceuticals, Inc. |
Targeting lipids
|
|
WO2009094391A1
(en)
|
2008-01-23 |
2009-07-30 |
Xencor, Inc. |
Optimized cd40 antibodies and methods of using the same
|
|
WO2009114335A2
(en)
|
2008-03-12 |
2009-09-17 |
Merck & Co., Inc. |
Pd-1 binding proteins
|
|
WO2009134389A2
(en)
|
2008-05-01 |
2009-11-05 |
Gtc Biotherapeutics, Inc. |
An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
|
|
KR20110039220A
(ko)
|
2008-06-30 |
2011-04-15 |
교와 핫꼬 기린 가부시키가이샤 |
항ｃｄ27 항체
|
|
CA2730742C
(en)
|
2008-07-16 |
2017-05-23 |
Baylor Research Institute |
Hiv vaccine based on targeting maximized gag and nef to dendritic cells
|
|
AU2010222928B2
(en)
|
2008-07-16 |
2012-11-29 |
Baylor Research Institute |
Antigen presenting cell targeted vaccines
|
|
WO2010007376A2
(en)
|
2008-07-18 |
2010-01-21 |
Domantis Limited |
Compositions monovalent for cd28 binding and methods of use
|
|
AR072571A1
(es)
|
2008-07-18 |
2010-09-08 |
Bristol Myers Squibb Co |
Composiciones monovalentes para union a cd28 y procedimientos de uso
|
|
US20110097339A1
(en)
|
2008-07-18 |
2011-04-28 |
Domantis Limited |
Compositions monovalent for CD28 binding and methods of use
|
|
JP5794917B2
(ja)
|
2008-09-12 |
2015-10-14 |
アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ |
Ｐｄ−１特異抗体およびその使用
|
|
US8927697B2
(en)
|
2008-09-12 |
2015-01-06 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
KR101814408B1
(ko)
|
2008-09-26 |
2018-01-04 |
다나-파버 캔서 인스티튜트 인크. |
인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
|
|
WO2010042433A1
(en)
|
2008-10-06 |
2010-04-15 |
Bristol-Myers Squibb Company |
Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
|
|
US8709411B2
(en)
|
2008-12-05 |
2014-04-29 |
Novo Nordisk A/S |
Combination therapy to enhance NK cell mediated cytotoxicity
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
WO2010082912A1
(en)
|
2009-01-15 |
2010-07-22 |
Avalon Pharmaceuticals |
Derivatives of multi-ring aromatic compounds and uses as anti-tumor agents
|
|
US8614295B2
(en)
|
2009-02-17 |
2013-12-24 |
Ucb Pharma S.A. |
Antibody molecules having specificity for human OX40
|
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
|
DK2406286T3
(en)
|
2009-03-10 |
2016-08-22 |
Baylor Res Inst |
Anti-cd40 antibodies and uses thereof
|
|
ES2571235T3
(es)
|
2009-04-10 |
2016-05-24 |
Kyowa Hakko Kirin Co Ltd |
Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
|
|
CA2759146C
(en)
|
2009-04-20 |
2017-06-13 |
Kyowa Kirin Co., Ltd. |
Agonist anti-cd40 antibody
|
|
WO2010132389A2
(en)
|
2009-05-14 |
2010-11-18 |
University Of Maryland, Baltimore |
Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
|
|
CN102762593B
(zh)
|
2009-07-31 |
2015-05-20 |
梅达雷克斯有限责任公司 |
抗btla的完全人抗体
|
|
EP2473531A4
(en)
|
2009-09-03 |
2013-05-01 |
Merck Sharp & Dohme |
Anti-gitr antibodies
|
|
WO2011031063A2
(ko)
|
2009-09-09 |
2011-03-17 |
울산대학교 산학협력단 |
항 4-1bb 항체를 포함하는 대사성 질환의 예방 또는 치료용 조성물
|
|
NZ628923A
(en)
|
2009-11-24 |
2016-02-26 |
Medimmune Ltd |
Targeted binding agents against b7-h1
|
|
MX346912B
(es)
|
2009-12-07 |
2017-04-05 |
Univ Leland Stanford Junior |
Metodos para mejorar terapia con anticuerpos antitumor.
|
|
EP2520589B1
(en)
|
2009-12-29 |
2018-11-07 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-cd27 antibody
|
|
KR20110085038A
(ko)
|
2010-01-19 |
2011-07-27 |
울산대학교 산학협력단 |
항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
|
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
|
EP2536764B1
(en)
|
2010-02-18 |
2018-07-04 |
OSE Immunotherapeutics |
Anti-cd28 humanized antibodies
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
JP5998060B2
(ja)
|
2010-03-04 |
2016-09-28 |
マクロジェニクス，インコーポレーテッド |
Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
|
|
BR112012024713B1
(pt)
|
2010-03-31 |
2021-02-17 |
Boehringer Ingelheim International Gmbh |
anticorpo humanizado, seus usos e composição farmacêutica que o compreende
|
|
WO2011127324A2
(en)
|
2010-04-08 |
2011-10-13 |
JN Biosciences, LLC |
Antibodies to cd122
|
|
EP3165540A1
(en)
|
2010-04-13 |
2017-05-10 |
Celldex Therapeutics, Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
WO2011155607A1
(ja)
|
2010-06-11 |
2011-12-15 |
協和発酵キリン株式会社 |
抗ｔｉｍ－３抗体
|
|
AU2011275749C1
(en)
|
2010-07-09 |
2015-09-17 |
Aduro Biotech Holdings, Europe B.V. |
Agonistic antibody to CD27
|
|
SMT201700185T1
(it)
|
2010-08-23 |
2017-05-08 |
Univ Texas |
Anticorpi anti-ox40 e metodi di uso degli stessi
|
|
PT2614082T
(pt)
|
2010-09-09 |
2018-12-03 |
Pfizer |
Moléculas de ligação a 4-1bb
|
|
CA2812046A1
(en)
|
2010-09-15 |
2012-03-22 |
Alnylam Pharmaceuticals, Inc. |
Modified irna agents
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
CN106963947A
(zh)
|
2010-11-22 |
2017-07-21 |
伊纳特医药股份有限公司 |
Nk细胞调节治疗和用于治疗血液恶性疾病的方法
|
|
WO2012075111A1
(en)
|
2010-11-30 |
2012-06-07 |
Novartis Ag |
Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
|
|
CA2824278C
(en)
|
2010-12-20 |
2022-09-20 |
The Rockefeller University |
Modulating agonistic tnfr antibodies
|
|
US9956236B2
(en)
|
2011-02-07 |
2018-05-01 |
Cornell University |
Methods for increasing immune responses using agents that directly bind to and activate IRE-1
|
|
JP5458188B2
(ja)
|
2011-02-17 |
2014-04-02 |
協和発酵キリン株式会社 |
抗ｃｄ４０抗体の高濃度製剤
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
HUE065915T2
(hu)
|
2011-03-11 |
2024-06-28 |
Beth Israel Deaconess Medical Ct Inc |
Anti-CD40 antitestek és alkalmazásaik
|
|
ES2612914T3
(es)
|
2011-03-31 |
2017-05-19 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Anticuerpos dirigidos contra Icos y usos de los mismos
|
|
DK2699598T3
(en)
|
2011-04-19 |
2019-04-23 |
Pfizer |
COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
|
|
KR101970025B1
(ko)
|
2011-04-20 |
2019-04-17 |
메디뮨 엘엘씨 |
Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
|
|
BR112013026828A2
(pt)
|
2011-04-21 |
2016-11-29 |
Bristol Myers Squibb Co |
polipeptídeos de anticorpo que antagonizam cd40
|
|
SMT201800269T1
(it)
|
2011-04-25 |
2018-07-17 |
Daiichi Sankyo Co Ltd |
Anticorpo anti-b7-h3
|
|
CN113461819B
(zh)
|
2011-04-29 |
2024-01-02 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
SG10201603962TA
(en)
|
2011-05-25 |
2016-07-28 |
Innate Pharma Sa |
Anti-kir antibodies for the treatment of inflammatory disorders
|
|
US8841418B2
(en)
|
2011-07-01 |
2014-09-23 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to TIM3
|
|
AP2014007415A0
(en)
|
2011-07-11 |
2014-02-28 |
Glenmark Pharmaceuticals Sa |
Antibodies that bind to OX40 and their uses
|
|
JP6120848B2
(ja)
|
2011-08-15 |
2017-04-26 |
メディミューン，エルエルシー |
抗ｂ７−ｈ４抗体およびその使用
|
|
CA2845810C
(en)
|
2011-08-23 |
2017-03-28 |
Board Of Regents, The University Of Texas System |
Anti-ox40 antibodies and methods of using the same
|
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
WO2013067492A1
(en)
|
2011-11-03 |
2013-05-10 |
The Trustees Of The University Of Pennsylvania |
Isolated b7-h4 specific compositions and methods of use thereof
|
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
|
WO2013138586A1
(en)
|
2012-03-15 |
2013-09-19 |
Janssen Biotech, Inc. |
Human anti-cd27 antibodies, methods and uses
|
|
US9580398B2
(en)
|
2012-04-02 |
2017-02-28 |
The Trustees Of Columbia University In The City Of New York |
Compounds, compositions, and methods for modulating ferroptosis and treating excitotoxic disorders
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
HK1204557A1
(en)
|
2012-05-31 |
2015-11-27 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-l1
|
|
KR101566539B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
|
|
WO2014011973A2
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of Columbia University In The City Of New York |
Quinazolinone-based oncogenic-ras-selective lethal compounds and their use
|
|
US9268936B2
(en)
|
2012-07-27 |
2016-02-23 |
Mandiant, Llc |
Physical memory forensics system and method
|
|
JP6403166B2
(ja)
|
2012-08-03 |
2018-10-10 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
単一抗原抗ｐｄ−ｌ１およびｐｄ−ｌ２二重結合抗体およびその使用方法
|
|
WO2014035474A1
(en)
|
2012-08-30 |
2014-03-06 |
The General Hospital Corporation |
Compositions and methods for treating cancer
|
|
EP2892928B1
(en)
|
2012-09-03 |
2018-05-30 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Antibodies directed against icos for treating graft-versus-host disease
|
|
PL2904011T3
(pl)
|
2012-10-02 |
2018-01-31 |
Bristol Myers Squibb Co |
Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka
|
|
DK2907824T3
(en)
|
2012-10-11 |
2018-07-23 |
Daiichi Sankyo Co Ltd |
ANTIBODY-drug conjugate
|
|
EP2910573B1
(en)
|
2012-10-19 |
2020-02-19 |
Daiichi Sankyo Company, Limited |
Antibody-drug conjugate produced by binding through linker having hydrophilic structure
|
|
US9789182B2
(en)
|
2012-10-23 |
2017-10-17 |
Bristol-Myers Squibb Company |
Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer
|
|
JP2016011258A
(ja)
|
2012-10-26 |
2016-01-21 |
株式会社ペルセウスプロテオミクス |
抗ヒトｃｄ４０モノクローナル抗体及びその利用
|
|
JPWO2014065402A1
(ja)
|
2012-10-26 |
2016-09-08 |
株式会社ペルセウスプロテオミクス |
抗ヒトｃｄ４０モノクローナル抗体及びその利用
|
|
AU2013337903B2
(en)
|
2012-10-30 |
2018-08-16 |
Apexigen, Inc. |
Anti-CD40 antibodies and methods of use
|
|
AU2013361275B2
(en)
|
2012-12-19 |
2016-11-24 |
Amplimmune, Inc. |
Anti-human B7-H4 antibodies and their uses
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
AU2014244424A1
(en)
|
2013-03-14 |
2015-08-27 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
US20140322236A1
(en)
|
2013-03-15 |
2014-10-30 |
Sdix, Llc |
Anti-human adora2a antibodies
|
|
WO2014140374A2
(en)
|
2013-03-15 |
2014-09-18 |
Novo Nordisk A/S |
Monovalent cd27 antibodies
|
|
SMT201800503T1
(it)
|
2013-03-18 |
2018-11-09 |
Janssen Pharmaceuticals Inc |
Anticorpi anti-cd (ox40) umanizzati e loro usi
|
|
EP2981821B2
(en)
|
2013-04-02 |
2021-11-03 |
Merck Sharp & Dohme Corp. |
Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
|
|
BR112015029395A2
(pt)
|
2013-05-24 |
2017-09-19 |
Medimmune Llc |
Anticorpos anti-b7-h5 e seus usos
|
|
US9676853B2
(en)
|
2013-05-31 |
2017-06-13 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind PD-1
|
|
SG11201509982UA
(https=)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
|
WO2014209168A1
(ru)
|
2013-06-24 |
2014-12-31 |
Kim Ruslan Zynsonovich |
Автомобильный коммуникатор
|
|
GB201311487D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
|
CA2917858A1
(en)
|
2013-08-02 |
2015-02-05 |
Aduro Biotech Holdings, Europe B.V. |
Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
US10077305B2
(en)
|
2013-09-10 |
2018-09-18 |
Medimmune Limited |
Antibodies against PD-1 and uses thereof
|
|
WO2015051149A1
(en)
|
2013-10-04 |
2015-04-09 |
The Trustees Of Columbia University In The City Of New York |
Sorafenib analogs and uses thereof
|
|
WO2015069785A1
(en)
|
2013-11-06 |
2015-05-14 |
Bristol-Myers Squibb Company |
Combination of anti-kir and anti-cs1 antibodies to treat multiple myeloma
|
|
EP3791870A1
(en)
|
2013-12-02 |
2021-03-17 |
The Trustees of Columbia University in the City of New York |
Modulating ferroptosis and treating excitotoxic disorders
|
|
GB201322583D0
(en)
|
2013-12-19 |
2014-02-05 |
Alligator Bioscience Ab |
Antibodies
|
|
KR20160085888A
(ko)
|
2013-12-20 |
2016-07-18 |
에프. 호프만-라 로슈 아게 |
항-ang2 항체 및 cd40 작용제를 사용한 조합 요법
|
|
EP3094332B1
(en)
|
2014-01-15 |
2018-09-12 |
The Trustees of Columbia University in the City of New York |
Carbonyl erastin analogs and their use
|
|
EP3686219A1
(en)
|
2014-02-04 |
2020-07-29 |
Pfizer Inc |
Combination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
|
|
WO2015134988A1
(en)
|
2014-03-07 |
2015-09-11 |
Bristol-Myers Squibb Company |
Method of using antibody polypeptides that antagonize cd40 to treat ibd
|
|
AU2015264528A1
(en)
|
2014-05-21 |
2016-11-03 |
Kyowa Hakko Kirin Co., Ltd. |
Combination of an anti-CCR4 antibody and a 4-1BB agonist for treating cancer
|
|
SG10201912986PA
(en)
|
2014-05-28 |
2020-02-27 |
Agenus Inc |
Anti-gitr antibodies and methods of use thereof
|
|
EP3149040A1
(en)
|
2014-05-29 |
2017-04-05 |
Spring Bioscience Corporation |
Anti-b7-h3 antibodies and diagnostic uses thereof
|
|
MA40074A
(fr)
|
2014-05-30 |
2015-12-03 |
Univ Columbia |
Composés liant ras multivalents
|
|
PT3151921T
(pt)
|
2014-06-06 |
2019-11-21 |
Bristol Myers Squibb Co |
Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
|
|
WO2015188047A1
(en)
|
2014-06-06 |
2015-12-10 |
University Of Maryland, Baltimore |
ANTI-CD-137 MONOCLONAL ANTIBODIES WITH DISTINCT FcγR BINDING ABILITIES FOR TREATMENT OF CANCER OR AUTOIMMUNITY
|
|
US20170198044A1
(en)
|
2014-06-23 |
2017-07-13 |
Theramab Llc |
Compositions and methods for safe and effective immunotherapy
|
|
WO2016005421A1
(en)
|
2014-07-09 |
2016-01-14 |
Novo Nordisk A/S |
Motorized drug delivery device
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
EP3180087B1
(en)
|
2014-08-12 |
2019-03-13 |
Alligator Bioscience AB |
Combination therapies with anti cd40 antibodies
|
|
KR20170035945A
(ko)
|
2014-08-14 |
2017-03-31 |
에프. 호프만-라 로슈 아게 |
인간 cd40을 활성화시키는 항체 및 인간 pd-l1에 대한 항체의 병용 요법
|
|
US20170233485A1
(en)
|
2014-08-18 |
2017-08-17 |
Biogen Ma Inc. |
Anti-cd40 antibodies and uses thereof
|
|
US20170247455A1
(en)
|
2014-08-22 |
2017-08-31 |
Bristol-Myers Squibb Company |
Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
|
|
KR102485788B1
(ko)
|
2014-08-27 |
2023-01-09 |
메모리얼 슬로안 케터링 캔서 센터 |
항체, 조성물 및 용도
|
|
MY193723A
(en)
|
2014-08-29 |
2022-10-27 |
Hoffmann La Roche |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
|
JP6943760B2
(ja)
|
2014-09-12 |
2021-10-06 |
ジェネンテック， インコーポレイテッド |
抗ｂ７−ｈ４抗体及び免疫複合体
|
|
JP2017531427A
(ja)
|
2014-10-03 |
2017-10-26 |
デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド |
グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
US10259874B2
(en)
|
2014-10-27 |
2019-04-16 |
Agency For Science, Technology And Research |
Anti-TIM-3 antibodies
|
|
GB201419094D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-TIM-3-antibodies
|
|
EP3212227B1
(en)
|
2014-10-28 |
2020-01-15 |
Children's University Hospital Tübingen |
Treatment of pediatric bcp-all patients with an anti-kir antibody
|
|
CA2963720C
(en)
|
2014-10-29 |
2024-05-14 |
Seattle Genetics, Inc. |
Dosage and administration of non-fucosylated anti-cd40 antibodies
|
|
WO2016070001A1
(en)
|
2014-10-31 |
2016-05-06 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind b7-h4
|
|
PT3215532T
(pt)
|
2014-11-06 |
2019-12-18 |
Hoffmann La Roche |
Anticorpos anti-tim3 e métodos de utilização
|
|
PL3333191T3
(pl)
|
2014-12-11 |
2021-05-04 |
Pierre Fabre Médicament |
Przeciwciała przeciwko c10orf54 i ich zastosowania
|
|
US9963509B2
(en)
|
2014-12-23 |
2018-05-08 |
Full Spectrum Genetics, Inc. |
Anti-B7H3 binding compounds and uses thereof
|
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
|
WO2017058716A1
(en)
|
2015-09-28 |
2017-04-06 |
Vivace Therapeutics, Inc. |
Tricyclic compounds
|
|
US20190008961A1
(en)
|
2016-01-07 |
2019-01-10 |
The Broad Institute, Inc. |
Compounds and methods for increasing tumor infiltration by immune cells
|
|
WO2018118711A1
(en)
|
2016-12-19 |
2018-06-28 |
The Trustees Of Columbia University In The City Of New York |
Small molecule ferroptosis inducers
|
|
CN108409737B
(zh)
|
2017-02-10 |
2020-07-03 |
华东理工大学 |
4-甲氧基苯基取代四氢-β-咔啉哌嗪二酮类衍生物及其应用
|
|
WO2018218087A1
(en)
*
|
2017-05-24 |
2018-11-29 |
K-Gen, Inc. |
Methods of cancer treatment
|
|
US12213977B2
(en)
*
|
2017-06-28 |
2025-02-04 |
The Regents Of The University Of California |
Methods and compositions for treating melanoma
|